Kane Biotech (KNE) Investor update summary

Strategic transformation and leadership commitment

• Transitioned to a focused wound care company centered on biofilm-targeting technology.

• Leadership and board express strong commitment to long-term value and disciplined capital stewardship.

• Management rebuilt credibility, strengthened relationships, and advanced commercial activities.

• Board and management aligned on transparency, governance, and sustainable growth.

• Presentations by board chair, leading wound-care surgeon, and interim CEO to discuss strategy and execution priorities.

Product platform, clinical validation, and regulatory status

• Revyve platform includes FDA and Health Canada-cleared gel, spray, and cleanser for chronic wounds and burns.

• Clinical evidence and real-world data show significant wound healing and pain reduction, including in complex cases.

• Clinician testimonials highlight unique biofilm disruption and patient-centric benefits.

• ISO 13485:2016 certification achieved under the Medical Device Single Audit Program.

• Ongoing and planned trials in new patient populations, including burns and military use.

Commercialization and market expansion

• Distribution network expanded to seven U.S. distributors and three in Canada, with additional agreements in progress.

• Targeting CAD 400,000 in sales for 2026, with a conservative ramp modeled through 2031.

• Plans to enter Europe via CE Mark in 2027; discussions with potential EU partners underway.

• Military and VA channels being developed, with research collaborations and distribution agreements.

• Ongoing efforts to strengthen commercial foundation and expand routes to market.